Diamyd Medical AB

About Diamyd Medical AB

Diamyd Medical is a company focused on developing precision therapies for Type 1 Diabetes. Their mission is to stop Type 1 Diabetes in its tracks by creating disease-modifying treatments, with a particular emphasis on preserving and regenerating patients' insulin production.

Products & Services

Diamyd®:An antigen-specific immunotherapy in clinical development phase, aimed at preserving and regenerating patients' own insulin production. It is being tested in the Phase III trial DIAGNODE-3 for efficacy in Type 1 Diabetes and in the Phase II trial DiaPrecise for prevention.

GAD65:A biological product available for preclinical research, with manufacturing facilities being set up in Umeå, Sweden.

Specialties

Precision Immunotherapy Type 1 Diabetes Therapies Intralymphatic Administration Antigen-Specific Immunotherapy

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1750000 MR: - FA: USD 1.75 million FAN: 1750000	D: 2025-02-12 FD: 2025-02-12	1 investors

Grant Latest

2025-02-12

$1.8M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mark Atkinson

Board Member

E

Emily K. Sims

Associate Professor of Pediatrics

A

Alice Long

Associate Member and Principal Investigator

Å

Åke Lernmark

Professor in Experimental Diabetes Research

D

David Leslie

Professor of Diabetes and Autoimmunity

A

Anders Essen-Möller

Chairman

View 17 more team members with Pro

Unlock Full Team Directory

Recent News